Italian consortium acquiring Esso fuel stations in strategic financial deal - Global Banking & Finance Review
The image depicts the acquisition of Esso's 1,200 fuel stations by an Italian consortium, highlighting the strategic impact on Italy's fuel distribution network.
Finance

Drugmaker Rovi's net profit rises on higher Okedi, heparin sales

Published by Global Banking & Finance Review

Posted on February 25, 2026

2 min read

· Last updated: February 25, 2026

Add as preferred source on Google

Rovi Net Profit Up 3% on Strong Okedi and Heparin Sales in 2025

Okedi and Heparin Sales

Net Profit Up 3%

Earnings and Sales Drivers

Feb 25 (Reuters) - Spanish drugmaker Laboratorios Farmaceuticos Rovi said on Wednesday its 2025 net profit rose 3% as higher sales of its schizophrenia drug Okedi and heparin products - as well as recognition of R&D aid - offset a decline in contract manufacturing revenue.

* Full-year net profit rose to 140.4 million euros, whileoperating revenue fell 3% to 743.5 million euros * CDMO revenue dropped 20% to 269.5 million euros onnegligible Moderna-related revenue and lower production volumesfor Moderna * Specialty pharmaceutical revenue increased 11% to 473.9million euros, driven by a 97% rise in Okedi sales and 7% in theheparin franchise, which includes low molecular weight heparins(LMWH) and other heparins * Gross profit rose 3% to 494.7 million euros, supported by36.3 million euros in R&D aid and lower LMWH raw material prices * Rovi will propose a dividend of 0.96 euros per share, apayout of around 35% * It expects 2026 operating revenue to grow by a highsingle-digit to low double-digit percentage
Reporting and Editing Credits

(Reporting by Marta Serafinko in Gdansk; Editing by David Latona)

Key Takeaways

  • Rovi's 2025 net profit increased 3% to €140.4m. (marketscreener.com)
  • Specialty pharma revenue grew 11%, with Okedi sales up 97% and heparins up 7%. (europapress.es)
  • CDMO revenue declined amid reduced vaccine-related volumes from Moderna. (rovi.es)
  • Gross profit rose 3% to €494.7m, aided by €36.3m in R&D aid and lower LMWH raw material prices. (europapress.es)
  • Rovi proposes a €0.9594/share dividend (~35% payout) and guides 2026 operating revenue to rise high single- to low double-digit. (marketscreener.com)

References

Frequently Asked Questions

What is the main topic?
Rovi reported 2025 results: net profit up 3% to €140.4m as growth in Okedi and heparins offset weaker CDMO revenue. It also proposed a dividend and issued 2026 growth guidance. ([marketscreener.com](https://www.marketscreener.com/news/laboratorios-farmaceuticos-rovi-s-a-2025-results-press-release-ce7e5cdbda89f521))
How did Okedi and the heparin franchise perform?
Okedi sales jumped 97% to €56.7m, while the heparin franchise rose 7% to €266.8m in 2025, driven by stronger partner orders. ([europapress.es](https://www.europapress.es/economia/noticia-rovi-gana-1404-millones-euros-2025-mas-pagara-dividendo-09594-euros-accion-20260225080509.html?utm_source=openai))
What is Rovi’s outlook for 2026?
Rovi expects operating revenue to increase by a high single- to low double-digit percentage, with potential support from a pending Bristol Myers Squibb manufacturing deal. ([marketscreener.com](https://www.marketscreener.com/news/laboratorios-farmaceuticos-rovi-s-a-2025-results-press-release-ce7e5cdbda89f521))

Tags

Related Articles

More from Finance

Explore more articles in the Finance category